Sun, 22 Nov 2026

Celebrate Naija

telling the Nigerian story

Business

Sage stock cut to hold at TD Cowen (NASDAQ:SAGE)

Business on Wall Street in Manhattan

Pgiam/iStock via Getty Images

Sage Therapeutics (NASDAQ:SAGE) traded lower on Tuesday as the company drew another downgrade on Wall Street—this time from TD Cowen—following its failure in a mid-stage trial for its neuro candidate SAGE-324 developed with Biogen (BIIB). ­

TD Cowen lowered itsBIIBSAGEknown as essential tremor last week.

Leave a Reply

Your email address will not be published. Required fields are marked *